Browse the evidence

First-line therapy for obesity involves lifestyle modification (energy-restricted diet and increased physical activity) aiming for 5-15% weight loss over 6 months, supported by pharmacotherapy or bariatric surgery for higher BMI or comorbidities.

Start with a 600 kcal daily deficit and 30-60 minutes of moderate exercise most days. Aim for 5-15% weight loss over 6 months. If BMI is >30 (or >27 with comorbidities), discuss pharmacotherapy (e.g., GLP-1 agonists) or bariatric surgery (if BMI >=40 or >=35 with comorbidities) with your doctor.

Semaglutide (2.4 mg weekly) and Liraglutide (3.0 mg daily) are effective pharmacological adjuncts for obesity, producing significant weight loss (15% and 8-10% respectively) when combined with lifestyle interventions.

For patients with BMI ≥ 30 (or ≥ 25 with comorbidities) who do not achieve goals with lifestyle changes alone, consider GLP-1 analogues. Semaglutide 2.4mg weekly yields ~15% weight loss; Liraglutide 3mg daily yields ~8-10%. These are adjuncts to, not replacements for, behavioral therapy.

Increased consumption of ultra-processed foods is a major contributor to the global pandemics of obesity, type 2 diabetes, and related non-communicable diseases.

Prioritize fresh and minimally processed foods in your diet. Be aware that ultra-processed foods (UPFs) are a major driver of obesity and metabolic disease. UPFs are industrially formulated products high in sugars, unhealthy fats, and sodium, and low in fiber and protein. They are designed to be hyper-palatable and addictive. To improve health, reduce UPF consumption and replace them with whole or minimally processed alternatives. Policy changes are needed to make healthy foods more accessible and affordable.

Weekly subcutaneous tirzepatide (5-15 mg) produces significant, dose-dependent weight loss (-15% to -21%) and improves cardiometabolic markers in adults with overweight/obesity, including those with type 2 diabetes.

If you have obesity or overweight with related health issues, weekly tirzepatide injections, combined with diet and exercise, can lead to significant weight loss (15-21%) and improve heart and metabolic health. Start with a low dose to minimize side effects, and gradually increase it as tolerated.

Weekly subcutaneous semaglutide (2.4 mg) produces significant weight loss (-10%) and improves cardiometabolic markers in adults with overweight/obesity, including those with type 2 diabetes.

If you have obesity or overweight with related health issues, weekly semaglutide injections, combined with diet and exercise, can lead to significant weight loss (around 10%) and improve heart and metabolic health. Start with a low dose to minimize side effects, and gradually increase it as tolerated.

Weekly subcutaneous liraglutide (3.0 mg) produces significant weight loss (-5.24 kg) and improves cardiometabolic markers in adults with overweight/obesity, though it is less effective than semaglutide 2.4 mg.

If you have obesity or overweight with related health issues, daily liraglutide injections, combined with diet and exercise, can lead to moderate weight loss (around 5 kg) and improve heart and metabolic health. Start with a low dose to minimize side effects, and gradually increase it as tolerated. Note that it may be less effective than other options like semaglutide.

Novel anti-obesity medications (AOMs), specifically GLP-1 receptor agonists like semaglutide (2.4 mg weekly), achieve >10% body weight loss and lead to MASH resolution and fibrosis regression in patients with fibrotic MASH, offering a viable alternative to lifestyle changes alone.

Semaglutide 2.4 mg weekly is now FDA-approved for fibrotic MASH. It effectively resolves MASH and regresses fibrosis in many patients, offering a powerful tool when lifestyle changes are insufficient.

Aggressive LDL cholesterol lowering with high-dose statins (e.g., atorvastatin 80mg) significantly reduces major cardiovascular events and induces regression of coronary atherosclerosis in patients with type 2 diabetes, even when baseline LDL levels are within normal ranges.

If you have Type 2 Diabetes, your risk of heart disease is significantly higher than the general population. Current medical guidelines recommend statin therapy for most diabetic patients, regardless of whether your cholesterol numbers look 'normal' on a standard test. Aggressive treatment with high-dose statins (like atorvastatin 80mg) is proven to shrink existing plaque in your arteries and significantly reduce your risk of heart attack and stroke. This is a primary prevention strategy that should be discussed with your doctor, especially if you have other risk factors like high blood pressure or smoking history.

SGLT2 inhibitors and GLP-1 receptor agonists provide significant cardiovascular protection and should be prioritized in women with type 2 diabetes and high cardiovascular risk.

If you have diabetes and heart risk factors, ask your doctor about SGLT2 inhibitors (like Jardiance/Farxiga) or GLP-1 agonists (like Ozempic/Victoza). These drugs protect your heart and kidneys beyond just lowering blood sugar. Standard sugar-lowering pills may not be enough for heart protection.

The Five-Times-Sit-to-Stand Test (FTSST) serves as a valid, safe, and affordable diagnostic tool for assessing functional mobility, identifying sarcopenia risk, and predicting falls or cognitive impairment in adults aged 50+.

Use the Five-Times-Sit-to-Stand Test as a simple, free health check. Sit in a standard chair, fold your arms, and stand up and sit down five times as fast as you can. Time yourself. Compare your time to age- and sex-specific reference values (available in this study) to gauge your functional mobility. Slower times may indicate higher risks for falls, sarcopenia, or cognitive decline, prompting a conversation with a healthcare provider.

A semi-mechanistic exposure-response model using semaglutide 2.4 mg once weekly can accurately predict individual 1-year weight loss outcomes based on baseline demographics and early weight data (up to 28 weeks).

If you are starting semaglutide 2.4 mg, do not judge the treatment's effectiveness solely on your weight at week 0 or even week 4. The model shows that predictions become highly accurate (MAE ~3kg) only after incorporating weight data from weeks 8, 16, or 28. Use early weigh-ins to recalibrate expectations with your doctor rather than stopping treatment prematurely due to perceived lack of efficacy.

Once-weekly subcutaneous semaglutide 2.4 mg, used as an adjunct to lifestyle interventions, produces substantial and sustained weight loss (mean 14.9% at 68 weeks) and improves cardiometabolic risk factors in adults with overweight or obesity.

If you have obesity or overweight with related health issues, once-weekly semaglutide 2.4 mg combined with a modest calorie deficit and regular exercise can lead to significant, sustained weight loss (around 15% on average) and better heart health markers. Start with the lowest dose to minimize stomach upset, and expect side effects like nausea to fade over time.

Once-weekly subcutaneous semaglutide 2.4 mg and tirzepatide 10-15 mg induce large, sustained reductions in body weight and waist circumference in adults with obesity without diabetes, significantly outperforming lifestyle interventions alone.

For individuals with obesity who have not achieved sustained weight loss through lifestyle changes alone, adding once-weekly semaglutide (2.4 mg) or tirzepatide (10-15 mg) to a lifestyle program can result in significant, clinically meaningful weight loss (12-19%) and waist circumference reduction. These treatments are generally well-tolerated, with side effects typically being mild gastrointestinal issues that diminish over time.

Tirzepatide (5-15 mg once weekly) produces superior weight loss (16-22.5% mean reduction) compared to placebo and other GLP-1 RAs by acting as a dual GLP-1 and GIP receptor agonist.

Tirzepatide is a once-weekly injection that significantly reduces body weight (16-22.5%) in adults with overweight or obesity. It works by mimicking two gut hormones (GLP-1 and GIP) to increase satiety and reduce food intake. Treatment starts at a low dose (2.5 mg) and increases every 4 weeks to minimize side effects like nausea. It is most effective when combined with lifestyle changes, including a caloric deficit and regular physical activity.

Once-weekly subcutaneous semaglutide 2.4 mg induces greater weight loss from baseline than placebo and once-daily liraglutide 3.0 mg in patients with overweight or obesity, with or without type 2 diabetes.

Semaglutide 2.4 mg is a once-weekly injection approved for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with comorbidities. It is taken alongside a calorie-controlled diet and increased physical activity. The dose starts low (0.25 mg) and increases every 4 weeks to 2.4 mg to minimize side effects. It is currently the most efficacious medication for weight loss, producing double-digit percentage body weight reductions over 1-2 years, superior to placebo and once-daily liraglutide.

Total Diet Replacement (TDR) using meal replacements in very-low-calorie diets (VLCDs) produces significantly greater weight loss (average >10 kg over 12 months) and superior diabetes remission rates compared to usual care or food-based diets.

If you have obesity or Type 2 Diabetes, using Total Diet Replacement (TDR) with meal replacements for 3-5 months, followed by maintenance with 1-2 meal replacements daily, is a clinically proven strategy. It leads to significantly more weight loss (average 10kg+) and higher diabetes remission rates than standard advice. Ensure you work with a healthcare provider for medical supervision, especially during the initial very-low-calorie phase.

Meal replacement interventions improve cardiometabolic health outcomes, including glycemic control, blood pressure, lipids, and liver fat, often independent of or proportional to the degree of weight loss.

Using meal replacements to lose weight not only helps you shed pounds but also significantly improves your blood sugar, blood pressure, and liver health. This is especially true if you have Type 2 Diabetes, where significant weight loss can lead to remission.

Once-weekly subcutaneous semaglutide 2.4 mg, used as an adjunct to lifestyle intervention, significantly improves cardiometabolic risk factors—including waist circumference, HbA1c, blood pressure, and lipid profiles—in adults with overweight or obesity, with or without type 2 diabetes.

If you have obesity or overweight with related health risks, once-weekly semaglutide 2.4 mg, combined with a calorie-reduced diet and regular exercise, significantly improves key health markers like blood pressure, blood sugar, and cholesterol. This treatment is most effective when used long-term, as stopping it can reverse these benefits.

High-dose GLP-1 receptor agonists (semaglutide 2.4 mg and tirzepatide 15 mg) produce substantial, clinically significant weight loss in adults with obesity, with tirzepatide demonstrating superior efficacy compared to other agents.

If you have obesity, high-dose GLP-1 medications like semaglutide (2.4 mg weekly) or tirzepatide (15 mg weekly) are significantly more effective for weight loss than lifestyle changes alone. Tirzepatide showed the highest efficacy in this review. These treatments work by targeting hormonal pathways that regulate hunger and satiety, and they are most effective when combined with standard lifestyle counseling.

Tirzepatide administered once weekly produces significant weight loss (mean difference -16.32% body weight) and improves cardiometabolic markers (BMI, waist circumference, lipids, blood pressure) in patients with overweight or obesity without diabetes mellitus, though it carries a significantly elevated risk of gastrointestinal side effects.

For individuals with overweight or obesity without diabetes, tirzepatide is a highly effective pharmacological intervention for weight loss, producing greater reductions than GLP-1 RAs like semaglutide. It also improves blood pressure, lipids, and glycemic control. However, patients must be prepared for a high likelihood of gastrointestinal side effects (nausea, vomiting, diarrhea), which can lead to discontinuation. The overall risk of serious adverse events is not significantly higher than placebo, but the burden of GI symptoms is a key consideration for adherence.

GLP-1 receptor agonists significantly increase the likelihood of achieving weight loss compared to placebo, with tirzepatide and semaglutide demonstrating the highest relative efficacy among evaluated agents.

If you have obesity or overweight with related health issues, GLP-1 receptor agonists like semaglutide or tirzepatide are highly effective pharmacological options. They work by mimicking a hormone that reduces hunger and slows digestion. Clinical data shows they significantly increase the chance of losing weight compared to placebo, with tirzepatide and semaglutide showing the best results. These medications are FDA-approved for chronic weight management and should be used in combination with lifestyle changes.

Once-weekly semaglutide 2.4 mg delivers significant weight loss (approx. 15-16% in non-diabetics, 9.6% in diabetics) and improves cardiovascular risk factors, and is FDA-approved for chronic weight management in adults with BMI ≥30 kg/m2 or ≥25 kg/m2 with comorbidities.

If you have type 2 diabetes and struggle with weight, once-weekly semaglutide 2.4 mg is a highly effective, FDA-approved option. It can lead to nearly 10% body weight loss when combined with lifestyle changes. While you may experience some gastrointestinal side effects, most people tolerate it well enough to stay on the medication, which is crucial for maintaining the weight loss and improving heart health markers.

Bariatric-metabolic surgery (Roux-en-Y gastric bypass or sleeve gastrectomy) significantly increases the probability of histological NASH resolution without worsening fibrosis compared to lifestyle modification plus best medical care in patients with obesity and NASH.

For individuals with obesity and confirmed NASH, bariatric surgery (Roux-en-Y or sleeve gastrectomy) is a highly effective treatment for resolving liver inflammation and fibrosis, far outperforming lifestyle changes and medical therapy alone. This should be considered a primary treatment option for eligible patients.

GLP-1 receptor agonists (GLP-1 RAs) promote significant, sustained weight loss in adults with obesity (BMI ≥30 kg/m2) or overweight (BMI ≥27 kg/m2) with comorbidities, primarily through central nervous system-mediated appetite suppression and reduced caloric intake, with efficacy superior to previously approved anti-obesity medications.

GLP-1 agonists like semaglutide and liraglutide are FDA-approved for chronic weight management in adults with obesity or overweight with comorbidities. They work by targeting hormonal pathways in the brain to reduce hunger and increase satiety, leading to significant, sustained weight loss that is roughly double that of older medications. Treatment is available in daily or weekly injectable forms, as well as oral tablets, and is intended for long-term use to maintain results without the 'Yo-Yo' effect common with short-term diets.